Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Sees Significant Increase in Short Interest

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 56,400 shares, a growth of 12.8% from the August 15th total of 50,000 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 91,400 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inspira Technologies Oxy B.H.N. stock. Armistice Capital LLC purchased a new stake in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,528,000 shares of the company’s stock, valued at approximately $1,620,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

Inspira Technologies Oxy B.H.N. Stock Performance

Inspira Technologies Oxy B.H.N. stock traded up $0.01 on Monday, reaching $1.22. 35,657 shares of the stock were exchanged, compared to its average volume of 516,534. The company has a quick ratio of 2.13, a current ratio of 2.23 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $1.12 and a two-hundred day moving average price of $1.61. Inspira Technologies Oxy B.H.N. has a twelve month low of $0.76 and a twelve month high of $2.49.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.